Bryan T. Mayer

The paper develops a mechanistic model of vaccine-induced humoral responses, showing class-specific activation and competition among B cells, with stronger competition within classes.

The paper analyzes HIV breakthrough virus populations in antibody-mediated prevention trials, finding high rates of multilineage infections and recombination under VRC01 treatment.

This study identifies VRC01-mediated viral escape mutations in HIV-infected participants from antibody-mediated prevention trials, showing that VRC01 can select for escape variants with cross-resistance to other CD4bs bnAbs.

This paper develops a hydrogel depot system to prolong the release of broadly neutralizing antibodies, showing improved pharmacokinetics and reduced immune cell-mediated release through co-formulation with anti-inflammatory agents.

This study engineers an HIV broadly neutralizing antibody to improve its potency, antiviral activity, and manufacturability while maintaining safety and efficacy.

This paper identifies highly-conserved CRISPR guide RNAs for HIV cure and models the impact of viral diversity on therapeutic success.